AD in Adults - Optimal Management of Moderate to Severe AD in Adults - Optimal Management of Moderate to Severe Atopic Dermatitis: Infants, Adults, and Everyone in Between! - Internal Medicine

Optimal Management of Moderate to Severe AD in Adults

Experts review the latest in managing moderate to severe AD in adults, from Clinical Care Options (CCO).

Robert Sidbury, MD, MPH

Jonathan Silverberg, MD, PhD, MPH

Released: January 13, 2023

Information on this Educational Activity

Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:

Faculty

Robert Sidbury, MD, MPH

Professor, Department of Pediatrics
Chief, Division of Dermatology
Seattle Children's Hospital
University of Washington School of Medicine
Seattle, Washington

Robert Sidbury, MD, MPH: consultant/advisor/speaker: Beiersdorf, Leo, Lilly, Micreos; researcher: Castle, Galderma, Pfizer, Regeneron, UCB.

Jonathan Silverberg, MD, PhD, MPH

Professor
Director of Clinical Research
Director of Patch Testing
George Washington University School of Medicine and Health Sciences
Washington, DC

Jonathan I. Silverberg, MD, PHD, MPH: consultant/advisor: AbbVie, Aobiome, Arcutis, Amgen, Arena, Asana, Aslan, BioMX, Biosion, Bodewell, Boehringer Ingelheim, Cara, Castle Biosciences, Celgene, Connect Biopharma, Dermavant, Dermira, Dermtech, Galderma, GlaxoSmithKline, Incyte, Kiniksa, Leo, Lilly, Menlo, Novartis, Optum, Pfizer, RAPT, Regeneron, Sanofi, Shaperon, Union.

The planners and content peer reviewers from Clinical Care Options, LLC do not have any relevant financial relationships to disclose, except Kristine Kucera, PA-C, MPAS, DHSc and Victoria Garcia-Albea, NP, DCNP, as noted below:

Kristine Kucera, PA-C, MPAS, DHSc: consultant/advisor/speaker: AbbVie, Amgen, Beiersdorf, Bristol-Myers Squibb, Dermavant, Leo, Novartis, Sun, UCB.

Victoria Garcia-Albea, NP, DCNP: consultant/advisor/speaker: Sanofi-Genzyme

Target Audience

This education is intended for dermatologists, allergists, nurse practitioners, physician associates/physician assistants, nurses, and other healthcare professionals who treat pediatric and adult patients with moderate to severe atopic dermatitis.

Goal

The goal of this educational program is to improve learners’ knowledge and competence regarding improving the management of pediatric and adult patients with moderate to severe atopic dermatitis.

Program Medium

This program has been made available online.